ENDV ENDONOVO THERAPEUTICS, INC.
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 1528172 · Fiscal year ends 12/31
Financial factors as of 2023-09-30 (2023Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,699.9%
TTM net income YoY-40.0%
TTM EPS YoY—
Revenue 3-yr CAGR-5.5%
Net income 3-yr CAGR—
Margins
Gross margin96.2%
Operating margin-1,023.2%
Net margin-1,722.2%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-388.5%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets2,914.6%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.14x
Accruals ratio-333.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 | FY20182018-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $135,355 | $73,105 | $165,796 | $310,164 | $83,263 |
| Cost of revenue | $9,990 | $14,985 | $65,369 | $93,385 | $12,930 |
| Gross profit | $125,365 | $58,120 | $100,427 | $216,779 | $70,333 |
| R&D expense | — | $0 | $3,283 | $153,126 | $274,265 |
| Operating income | -$3.26M | -$2.23M | -$2.91M | -$3.81M | -$4.16M |
| Interest expense | — | $941,566 | $2.08M | $17,000 | — |
| Pretax income | -$18.47M | -$3.10M | -$395,584 | -$17.31M | -$6.44M |
| Net income | -$18.47M | -$3.10M | -$395,584 | -$17.31M | -$6.44M |
| EBITDA | -$2.62M | -$1.58M | -$2.26M | -$3.16M | -$3.51M |
| EPS (basic) | -0.13 | -0.05 | -0.03 | -24.83 | -17.76 |
| EPS (diluted) | — | -0.05 | -0.03 | -24.83 | -17.76 |
| Weighted avg. shares (diluted) | — | 59.84M | 12.22M | 697,305 | 362,466 |
| Banking | |||||
| Net interest income | -$1.32M | -$941,566 | -$2.08M | -$6.09M | -$5.20M |
| Balance sheet | |||||
| Cash & equivalents | $98 | $85,936 | $13,420 | $18,893 | $379,151 |
| Receivables | — | $944 | $942 | $22,742 | $3,345 |
| Current assets | $15,822 | $94,855 | $46,187 | $62,555 | $382,496 |
| PP&E, net | — | — | $1,580 | $5,915 | $6,727 |
| Intangibles | $1.27M | $1.91M | $2.56M | $3.21M | $3.85M |
| Total assets | $1.28M | $2.01M | $2.61M | $3.27M | $4.24M |
| Current liabilities | $33.38M | $17.70M | $16.83M | $23.62M | $15.48M |
| Long-term debt | $7.15M | $7.26M | $6.84M | $6.87M | $8.16M |
| Total debt | $7.15M | $7.26M | $6.84M | $6.87M | $8.16M |
| Total liabilities | $33.46M | $17.78M | $16.98M | $23.78M | $15.63M |
| Shareholders' equity | -$32.18M | -$15.77M | -$14.37M | -$20.50M | -$11.39M |
| Net debt | $7.15M | $7.17M | $6.82M | $6.86M | $7.78M |
| Shares outstanding | 213.23M | 74.50M | 24.54M | 1.19M | 431,063 |
| Cash flow statement | |||||
| Operating cash flow | -$678,838 | -$986,584 | -$741,590 | -$2.54M | -$2.88M |
| Capital expenditure | — | — | — | $2,594 | $8,969 |
| Free cash flow | — | — | — | -$2.54M | -$2.89M |
| Investing cash flow | — | — | — | -$2,594 | -$8,969 |
| Financing cash flow | $593,000 | $1.06M | $736,117 | $2.18M | $3.18M |
| Depreciation & amortization | $646,912 | $648,492 | $651,247 | $650,315 | $650,216 |
| Stock-based compensation | $45,000 | $0 | $57,400 | $31,012 | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.